Ana Sousa

SVP, Regulatory Affairs & Quality at Aspen Neuroscience

Ana Sousa brings a depth of expertise to her role as Senior Vice President of Regulatory Affairs for Aspen Neuroscience. With twenty years of experience in global regulatory affairs, Ana combines large company experience with the agility of a small biotech mindset. Prior to Aspen, Ana led Global Regulatory Affairs and Quality for Principia Biopharma, where she focused on bringing transformative therapies to patients with serious immune-mediated diseases by changing the way small molecules are developed. As a member of the leadership team, she was instrumental in developing the regulatory and corporate strategy resulting in one of the most successful IPOs in 2018 with the subsequent acquisition of the company by Sanofi in 2020. Prior to Principia she held positions of increased leadership with Immune Design, Onyx Pharmaceuticals, and Genentech-Roche.

Ana received her undergraduate degree at Pace University, Lubin School of Business, and her Master of Science in Jurisprudence (MSJ) degree with a concentration in Health Law and Intellectual Property at The Seton Hall University School of Law.


  • SVP, Regulatory Affairs & Quality

    Current role